Clinical-stage focus Exegenesis Bio is a clinical-stage global gene therapy company with two programs in late-stage development (SMA in China and neurovascular AMD in the USA), presenting multiple partnership and collaboration opportunities to accelerate program timelines, regulatory strategies, and market access.

Capid and delivery tech The company emphasizes proprietary capsids, promoters, and protein engineering for AAV delivery, plus a next-generation deep-retinal delivery approach (EXG202). This suggests opportunities to position as a partner for novel delivery platforms, combination therapies, or co-development with suppliers and CROs focused on ocular and CNS targets.

Manufacturing capacity State-of-the-art cGMP facilities with large-scale disposable bioreactors and plasmid fermenters indicate readiness for scalable vector production, offering potential collaborations in manufacturing, tech transfer, fill-finish services, or contract manufacturing partnerships to support expanded clinical trials and potential commercialization.

Global footprint Operations in Philadelphia, Boston, and China, along with a history of international expansion and multiple ASGCT presentations, point to cross-border collaboration potential, regional licensing deals, and access to diverse regulatory environments for joint development and market entry strategies.

Funding and scale Raised over 150 million since 2019 with a current revenue range of 25–50 million and a growing scientific workforce, signaling willingness to engage in strategic partnerships, co-development agreements, and financed deals to accelerate clinical programs and expand capabilities.